China's potential Covid-19 vaccine to be tested in Brazil
Sinopharm's candidate vaccine is already being tested in the United Arab Emirates with 15,000 volunteers.
Chinese drug company Sinopharm and Brazil's Parana state agree to launch the fourth major Covid-19 vaccine trial, with regulatory approval to be sought in the next two weeks.
A trial by Sinopharm would join Phase III trials already announced in Brazil by AstraZeneca, Sinovac Biotech and a Pfizer partnership with BioNTech.
Jorge Callado, head of the Parana Technology Institute (Tecpar), said on Wednesday they would soon finalise their proposal and submit it for approval with federal health regulator Anvisa.
Brazil's Covid-19 outbreak, the world's worst outside the United States, has made it global testing ground for potential vaccines.
Sinopharm's candidate vaccine is already being tested in the United Arab Emirates with 15,000 volunteers.
Six coronavirus vaccines are now in phase III of human trials and one has been approved:
— Denis Wirtz (@deniswirtz) July 28, 2020
They include:
Moderna/NIH (US)
BioNTech/Pfizer/Fosum (US/China)
AstraZeneca/U. Oxford (Sweden/UK)
Sinopharm (China)
Sinovac (China)
as well as CanSino (approved, China)
(source: NYT) pic.twitter.com/yBolPXuUpp
Parana is also in talks with Russian researchers about producing their potential vaccine, the state government said in a statement, adding that Governor Ratinho Junior would soon meet with Russia's ambassador to Brazil.
Russians have also contacted Sao Paulo's Butantan Institute to discuss testing their vaccine, the institute's director told reporters on Wednesday.